About this trial
TARGET-METABOLIC is an observational research study to conduct a comprehensive review of outcomes for patients with metabolic syndrome and related conditions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Death
Manual removal (sponsor or site request)
No EHR interface encounter > 3 years
Adult patients diagnosed and managed for these conditions invited to participate
Trial population
The study will include adults with metabolic syndrome and related conditions.
Trial design
Cohort
Other
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
To characterize the natural history of disease in patients with metabolic syndrome and related conditions
A detailed analysis of available demographics, anthropometric characteristics, glycemic metrics, medications, co-morbidities, and medical history from sites across the US will inform the profile for various patient populations enrolled into the study. Collection of detailed medical records will be curated and analyzed to characterize disease natural history, clinical course of disease, number and types of interventions, current treatment paradigms, and the patient diagnostic journey. These data may also establish incidence rates of events of special interest. Collection of prospective medical records for each patient enables the continuation of these analyses longitudinally for changes and progression to characterize the clinical course of disease. The progression of pre-existing co-morbidities and variances across populations will also be evaluated.
To assess safety and effectiveness of treatments for metabolic syndrome and related conditions.
The study will evaluate the characteristics of patients receiving various treatments, effectiveness of treatment, and medical events that develop while receiving treatment for metabolic syndrome and related conditions. Treatments may be pharmacologic, surgical, procedures, radiologic or other interventions given to change the disease course/outcomes. Interval disease and medical events may vary depending on the patient's stage and type of disease and extent of co-morbidities at study entry and time of diagnosis.
Secondary outcomes
To evaluate provider management practices in the treatment of patients with metabolic syndrome and related conditions
Health care provider type, clinic setting, reason for initiating/not initiating/adjusting dosing of treatments or interventions (i.e., surgery, radiation), reason for discontinuing/switching treatments, and monitoring outcomes on and off treatment, will be captured as available in the provided EHR and/or through linked data. Disease-specific quality measures will be selected and evaluated, and the curated data can enable analyses to describe and evaluate healthcare utilization patterns.
To evaluate longitudinal and patient reported outcomes in patients with metabolic syndrome and related conditions
Longitudinal clinical outcomes and disease progression will be assessed. Self-reported patient health measures collect information directly from patients to measure physical, mental, and social health. These measures can help clinicians better understand how the disease state and/or various treatments affect what patients are able to do and the symptoms they experience beyond what is typically derived and reported in the EHR as part of traditional clinical evaluations. The information can also be used to help patients make informed decisions about their healthcare and treatment options.
To select and evaluate quality of care measures for patients with metabolic syndrome and related conditions
1. Identify deficiencies and select best practices in care of patients 2. Develop a technology infrastructure to evaluate quality measures to support clinicians.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: